Stock Events

Stock Events

Gilead Sciences 

CL$99,603.44
2861
+CL$99,493.01+90,096% Friday 13:30

Statistics

Day High
110.29
Day Low
110.29
52W High
99,603.44
52W Low
110.29
Volume
0
Avg. Volume
0
Mkt Cap
123.5T
P/E Ratio
17.55
Dividend Yield
3.06%
Dividend
3,052.24

Upcoming

Dividends

3.06%Dividend Yield
Sep 26
CL$765.79
Jun 26
CL$755.84
Mar 26
CL$762.78
Dec 25
CL$710.95
Sep 25
CL$762.30
10Y Growth
9.56%
5Y Growth
7.93%
3Y Growth
5.86%
1Y Growth
1.45%

Earnings

22OctExpected
Q2 2024
Q4 2024
Q4 2024
Q2 2025
Q4 2025
Q2 2026
Next
-7.25
-4.13
-1
2.12
Expected EPS
2.117385
Actual EPS
N/A

Financials

28.98%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
27.46TRevenue
7.96TNet Income

Analyst Ratings

81,265.41Average Price Target
The highest estimate is 90,472.30.
From 10 ratings within the last 6 months. This is not an investment recommendation.
Buy
70%
Hold
30%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow GILD.SN. It's not an investment recommendation.
Apple
603
AAPL
Abbvie
576
ABBV
Realty Income
575
O
Microsoft
570
MSFT

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Abbvie
ABBV
Mkt Cap453.19B
AbbVie competes directly with Gilead in the areas of hepatitis C treatments and is also a major player in immunology and oncology.
Merck
MRK
Mkt Cap370.89B
Merck & Co. offers competitive products in the antiviral space, including treatments for HIV and hepatitis C, directly challenging Gilead's core market.
Pfizer
PFE
Mkt Cap162.16B
Pfizer competes across several therapeutic areas including oncology, immunology, and antiviral drugs, overlapping with Gilead's product portfolio.
Bristol-Myers Squibb
BMY
Mkt Cap136.49B
Bristol Myers Squibb is a key competitor in the oncology and immunology sectors, areas where Gilead Sciences is actively expanding its presence.
Johnson & Johnson
JNJ
Mkt Cap663.28B
Johnson & Johnson, through its pharmaceutical segment Janssen, competes in the HIV and hepatitis C markets, among others, where Gilead has significant interests.
AMGEN
AMGN
Mkt Cap236.38B
Amgen competes with Gilead in the biopharmaceutical space, particularly in the areas of oncology and inflammatory diseases.
GSK
GSK
Mkt Cap99.96B
GlaxoSmithKline, through its ViiV Healthcare joint venture, is a strong competitor in the HIV treatment market, directly challenging Gilead's leadership.
Novartis
NVS
Mkt Cap304.1B
Novartis competes with Gilead in several areas including oncology and gene therapy, with both companies investing heavily in research and development.
Roche
RHHBY
Mkt Cap334.28B
Roche, through its Genentech unit, competes in the oncology and antiviral markets, areas where Gilead has key products.
Astrazeneca
AZN
Mkt Cap252.33B
AstraZeneca competes with Gilead in the oncology sector, with both companies developing treatments for various cancers.

About

Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Show more...
CEO
Daniel O'Day
Employees
17000
Country
United States
ISIN
US3755581036
WKN
000885823

Listings

BOATS
BOATS
GILD.BOATS
F
DE
GIS.F
SN
CL
GILDCL.SN
LSE
GB
0QYQ.LSE

0 Comments

Share your thoughts

FAQ

What is Gilead Sciences stock price today?▼
The current price of GILD.SN is CL$99,603.44 CLP — it has increased by +90,096% in the past 24 hours. Watch Gilead Sciences stock price performance more closely on the chart.
What is Gilead Sciences stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Chilean Stock Exchange exchange Gilead Sciences stocks are traded under the ticker GILD.SN.
Is Gilead Sciences stock price growing?▼
GILD.SN stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year Gilead Sciences has showed a +0% increase.
What is Gilead Sciences market cap?▼
Today Gilead Sciences has the market capitalization of 123.5T
When is the next Gilead Sciences earnings date?▼
Gilead Sciences is going to release the next earnings report on October 22, 2026.
What were Gilead Sciences earnings last quarter?▼
GILD.SN earnings for the last quarter are -6,172.61 CLP per share, whereas the estimation was -6,626.71 CLP resulting in a +6.85% surprise. The estimated earnings for the next quarter are N/A CLP per share.
What is Gilead Sciences revenue for the last year?▼
Gilead Sciences revenue for the last year amounts to 27.46T CLP.
What is Gilead Sciences net income for the last year?▼
GILD.SN net income for the last year is 7.96T CLP.
Does Gilead Sciences pay dividends?▼
Yes, GILD.SN dividends are paid quarterly. The last dividend per share was 755.84 CLP. As of today, Dividend Yield (FWD)% is 3.06%.
How many employees does Gilead Sciences have?▼
As of September 08, 2026, the company has 17,000 employees.
In which sector is Gilead Sciences located?▼
Gilead Sciences operates in the Health & Wellness sector.
When did Gilead Sciences complete a stock split?▼
The last stock split for Gilead Sciences was on January 28, 2013 with a ratio of 2:1.
Where is Gilead Sciences headquartered?▼
Gilead Sciences is headquartered in FOSTER CITY, United States.